Who are BGB-15025's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Komzifti, MK-8527, BMS-986365.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bgb-15025.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BGB-15025 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BGB-15025 (BGB-15025) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Menin inhibitor. Area: Oncology.

phase 3 Menin inhibitor Menin (MEN1 protein) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BGB-15025 (BGB-15025) — BeiGene. BGB-15025 is a selective inhibitor of menin that disrupts the interaction between menin and mixed-lineage leukemia (MLL) proteins, restoring normal gene expression in acute leukemias.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BGB-15025 TARGET	BGB-15025	BeiGene	phase 3	Menin inhibitor	Menin (MEN1 protein)
Komzifti	ZIFTOMENIB	Kura	marketed	Menin Inhibitor [EPC]		2025-01-01
MK-8527	MK-8527	Merck Sharp & Dohme LLC	phase 3	Menin inhibitor	Menin (MEN1 protein)
BMS-986365	BMS-986365	Celgene	phase 3	Menin inhibitor	Menin (MEN1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Menin inhibitor class)

BeiGene · 1 drug in this class
Celgene · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BGB-15025 — Competitive Intelligence Brief. https://druglandscape.com/ci/bgb-15025. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing